Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Patients with hormone and docetaxel refractory prostate cancer or relapsed/refractory
non-Hodgkin's lymphoma for which no available standard therapy or therapy which may provide
clinical benefit is available will be enrolled. Primary objectives: estimate the maximum
tolerated dose and dose-limiting toxicities. Secondary objectives: Response rate,
pharmacokinetic and pharmacodynamic profiles, Prostate Specific Antigen response and renal
elimination.